Compare FISV & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FISV | NTRA |
|---|---|---|
| Founded | 1984 | 2003 |
| Country | United States | United States |
| Employees | 38000 | N/A |
| Industry | Real Estate | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.1B | 32.9B |
| IPO Year | N/A | 2015 |
| Metric | FISV | NTRA |
|---|---|---|
| Price | $60.37 | $198.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 28 | 14 |
| Target Price | $146.17 | ★ $253.79 |
| AVG Volume (30 Days) | ★ 8.6M | 967.7K |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $210,939,000.00 |
| Revenue This Year | N/A | $34.18 |
| Revenue Next Year | $4.31 | $16.69 |
| P/E Ratio | $9.94 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $57.79 | $125.38 |
| 52 Week High | $70.41 | $256.36 |
| Indicator | FISV | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 45.77 | 36.71 |
| Support Level | $57.79 | $195.46 |
| Resistance Level | $68.87 | $251.09 |
| Average True Range (ATR) | 2.46 | 7.68 |
| MACD | 0.21 | 0.23 |
| Stochastic Oscillator | 41.69 | 22.27 |
Fiserv is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing, for US banks and credit unions, with a focus on small and midsize banks. Following its 2019 merger with First Data, Fiserv also provides payment processing services to merchants. About 10% of the company's revenue is generated internationally.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.